Search Results 1-10 of 17437 for SC

  1. Kimberly G. Blumenthal, M.D., M.Sc. - Doctors and Medical Staff - Mayo Clinic

    Blumenthal, M.D., M.Sc. Allergist-Immunologist. Request an Appointment · Overview. Departments. Pulmonary Medicine · Allergic Diseases. Location. Jacksonville ...

  2. Gastroenterology and Hepatology - Clinical trials

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  3. A Study of SC-007 in Subjects With Advanced Cancer - Mayo Clinic

    This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC ...

  4. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

    Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended ...

  5. Michael Camilleri, M.D., D.Sc. - Mayo Clinic Faculty Profiles

    Focus areas · Diabetic gastroparesis. Dr. · Obesity. Dr. · Irritable bowel syndrome and chronic constipation. These conditions account for 25 percent of all ...

  6. Kimberly G. Blumenthal, M.D., M.Sc. - Doctors and Medical Staff - Mayo Clinic

    Blumenthal, M.D., M.Sc. Allergist-Immunologist. Request an Appointment · Overview. Departments. Pulmonary Medicine · Allergic Diseases. Location. Jacksonville ...

  7. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer - Mayo Clinic

    SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. Participation eligibility. Participant ...

  8. Kimberly G. Blumenthal, M.D., M.Sc. - Mayo Clinic Faculty Profiles

    Blumenthal, M.D., M.Sc., is a clinician-investigator in allergy and immunology. She focuses on improving population health and patient safety through ...

  9. SC Versus IV Isatuximab In Combination With Pomalidomide And Dexamethasone In RRMM - Mayo Clinic

    About this study. The purpose of this study is to demonstrate the efficacy non-inferiority between isatuximab SC and isatuximab IV in combination with ...

  10. Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy - Mayo Clinic

    Secondary objectives include efficacy measures of efgartigimod PH20 SC in participants with IIM. IIM is a disease of the immune system that causes weakness of ...